ROCKVILLE, Md.--(BUSINESS WIRE)-- Micromet, Inc. (Nasdaq: MITI), a biopharmaceutical company focused on the development and commercialization of next-generation antibodies for the treatment of cancer, announced today that the Company will participate in the 2011 UBS Global Life Sciences Conference, to be held September 19 - 21, 2011 in New York City. Christian Itin, Ph.D., Micromet’s President and Chief Executive Officer will present a 30 minute corporate overview on September 20th at 4:30 PM ET.
The presentation will be webcast live and may be accessed by visiting the Micromet website at www.micromet.com. A replay of the webcast will also be available on the Company's website.
About Micromet, Inc.
Micromet is a biopharmaceutical company focused on the discovery, development and commercialization of innovative antibody-based therapies for the treatment of cancer. The Company is advancing a robust pipeline of novel therapeutics based on its proprietary BiTE® technology. The Company's lead product candidate blinatumomab (MT103) is currently the subject of a European pivotal trial in patients with minimal residual disease positive acute lymphoblastic leukemia. Micromet has collaborations with a number of leading pharmaceutical and biotechnology companies, including Amgen, Bayer HealthCare Pharmaceuticals, Boehringer Ingelheim, MedImmune, Nycomed and Sanofi.
Jennifer Neiman, 240-235-0246
Director, Corporate Communications
KEYWORDS: United States North America Maryland
INDUSTRY KEYWORDS: Health Biotechnology Pharmaceutical